2018 completed, 614 recruiting, 574 terminated, 407 unknown. 1900 Phase 2, 1430 Phase 1, 418 Phase 3, 385 Not applicable, 106 Early Phase 1.
Follow this condition Literature Review of Neoplasms, Plasma Cell trials Research Report on Neoplasms, Plasma Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma Oncology-Embedded Cardiovascular Risk Assessment Pathway, Primary Care Provider-Directed Cardiovascular Risk Assessment Pathway - Multiple Myeloma, Heart Disease Risk Factors | Not applicable | Not yet recruiting | University of Vermont Medical Center | 33 | 2028-02-01 | 2026-08-25 |
| The Feasibility and Effects of Exercise on Patients Suffering From Multiple Myeloma Individual Exercise, Group Exercise - Multiple Myeloma | Not applicable | Suspended | Medical University of Vienna | 45 | 2027-09-01 | 2026-10-09 |
| Engineered Dendritic Cell Vaccines for Multiple Myeloma DC vaccines - Multiple Myeloma or Plasmacytoma | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 10 | 2027-06-30 | 2026-08-27 |
| ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide - Multiple Myeloma, Recurrent Multiple Myeloma | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2027-06-01 | 2026-09-11 | |
| Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 80 | 2027-05-22 | 2026-10-20 |
| Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Plasma Cell Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 74 | 2027-04-20 | 2026-10-07 |
| Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2027-04-12 | 2026-10-16 |
| Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy ceftazidime, ciprofloxacin, Standard-of-Care Antibiotic Strategy - Large B-Cell Lymphoma (LBCL), Multiple Myeloma (MM) | Phase 2 | Not yet recruiting | Zealand University Hospital | 150 | 2027-03-01 | 2026-09-25 |
| MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance, melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy - Multiple Myeloma (MM) | Phase 2 | Not yet recruiting | University of Arkansas | 50 | 2027-03-01 | 2026-09-02 |
| BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases. teclistamab OR talquetamab OR elranatamab OR linvoseltamab, BTK inhibitors (ibrutinib and zanubrutinib) - Waldenstrom Macroglobulinaemia, Multiple Myeloma | Phase 4 | Not yet recruiting | Anne Louise Tølbøll Sørensen | 400 | 2027-03-01 | 2026-03-16 |
| Microbiome Intervention for CAR-T Optimization and Response (MICRO-CART) Live Biotherapeutic Product (LBP), Placebo - Lymphoma, B-Cell, Multiple Myeloma | Phase 1 | Not yet recruiting | University of Chicago | 32 | 2027-02-23 | 2026-10-13 |
| Teclistamab In Waldenstrom's Macroglobulinemia Teclistamab - Waldenstrom's Macroglobulinemia | Phase 2 | Not yet recruiting | Massachusetts General Hospital | 24 | 2027-02-19 | 2026-09-01 |
| Early Prophylactic rhTPO Administration for Thrombocytopenia Associated With EAP Regimen-Based Hematopoietic Stem Cell Mobilization rhTPO prophylaxis plus EAP stem-cell mobilization - Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Hematopoietic Stem Cell Mobilization | Phase 2 / Phase 3 | Not yet recruiting | The Affiliated People's Hospital of Ningbo University | 70 | 2027-01-01 | 2026-09-30 |
| Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells Isatuximab, VRD - Multiple Myeloma | Phase 2 / Phase 3 | Not yet recruiting | The Affiliated People's Hospital of Ningbo University | 15 | 2027-01-01 | 2026-10-02 |
| A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma Anitocabtagene autoleucel, Daratumumab, Bortezomib - Newly Diagnosed Multiple Myeloma | Phase 3 | Not yet recruiting | Kite, A Gilead Company | 600 | 2027-01-01 | 2026-10-21 |
| Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma CAR T cells - Multiple Myeloma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 20 | 2026-12-31 | 2026-08-27 |
| Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma CAR-T cells - Multiple Myeloma, Plasmacytoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 20 | 2026-12-31 | 2026-08-27 |
| Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma Etentamig, Isatuximab, Bortezomib + Lenalidomide + Dexamethasone - Myeloma Multiple, Myeloma | Phase 1 / Phase 2 | Not yet recruiting | Universitätsklinikum Hamburg-Eppendorf | 220 | 2026-12-01 | 2026-05-20 |
| Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE) Belamaf, Cevostamab, Pomalidomide - Relapsed Refractory Multiple Myeloma (RRMM) | Phase 1 | Not yet recruiting | Canadian Myeloma Research Group | 108 | 2026-12-01 | 2026-09-21 |
| REal World MAIA UK OutcomEs Myeloma | Not yet recruiting | The Royal Wolverhampton Hospitals NHS Trust | 300 | 2026-12-01 | 2026-09-15 |
Showing 20 of 4349. Sign in to see all of them.
Multiple Myeloma (3658) · Lymphoma (651) · Lymphoma, Non-Hodgkin (626) · Leukemia, Lymphocytic, Chronic, B-Cell (610) · Waldenstrom Macroglobulinemia (521) · Lymphoma, Follicular (489) · Lymphoma, B-Cell, Marginal Zone (472) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (469) · Hodgkin Disease (468) · Lymphoma, Mantle-Cell (468) · Recurrence (438) · Lymphoma, Large B-Cell, Diffuse (428) · Leukemia (415) · Leukemia, Myeloid, Acute (381)
Neoplasms by Histologic Type (4335) · Immune System Diseases (4261) · Immunoproliferative Disorders (4256) · Lymphoproliferative Disorders (4203) · Hemic and Lymphatic Diseases (4148) · Neoplasms (4116) · Paraproteinemias (4115) · Hematologic Diseases (4064) · Cardiovascular Diseases (4019) · Blood Protein Disorders (4017) · Vascular Diseases (4011) · Hemorrhagic Disorders (4010) · Hemostatic Disorders (4004) · Lymphatic Diseases (1344)
Dexamethasone (910) · Bortezomib (515) · Lenalidomide (486) · Cyclophosphamide (403) · Melphalan (283) · Calcium Dobesilate (271) · daratumumab (253) · pomalidomide (226) · carfilzomib (192) · fludarabine phosphate (158) · fludarabine (141) · Peripheral Blood Stem Cell Transplantation (137) · Thalidomide (132) · Filgrastim (128) · Rituximab (127)
National Cancer Institute (NCI) (186) · Mayo Clinic (101) · Celgene (93) · Memorial Sloan Kettering Cancer Center (90) · M.D. Anderson Cancer Center (86) · Fred Hutchinson Cancer Center (85) · Janssen Research & Development, LLC (66) · University of Arkansas (59) · Dana-Farber Cancer Institute (55) · Institute of Hematology & Blood Diseases Hospital, China (53) · GlaxoSmithKline (47) · Amgen (43) · Washington University School of Medicine (41) · City of Hope Medical Center (39) · Masonic Cancer Center, University of Minnesota (37)
United States (2576) · China (491) · France (435) · Spain (337) · Germany (325) · Italy (324) · Canada (282) · United Kingdom (269) · Australia (232) · Greece (184) · South Korea (171) · Japan (166) · Belgium (156) · Israel (143) · Netherlands (143)
Brenda Sandmaier (12) · Robert Knight, MD (11)
PMID 32499241, PMID 33357481, PMID 31221778, PMID 37022569, PMID 22689675, PMID 23065508, PMID 23524640, PMID 33218965, PMID 34398557, PMID 35285981, PMID 37192741, PMID 40501401, PMID 28803351, PMID 29567784, PMID 34289038, PMID 35549810, PMID 35985959, PMID 36100310, PMID 38023148, PMID 40000533, PMID 40226119, PMID 40826257, PMID 42287565, PMID 20661232, PMID 22674807, PMID 23897961, PMID 25261096, PMID 25628469, PMID 34182226, PMID 34515338, PMID 35876974, PMID 36762851, PMID 37272512, PMID 37934000, PMID 38402374, PMID 39229471, PMID 40156952, PMID 40396505, PMID 40471585, PMID 40674744, PMID 41313549, PMID 41627370, PMID 18032762, PMID 18032763, PMID 18799726, PMID 19179301, PMID 19238148, PMID 19901114, PMID 20067838, PMID 21160068
2023 (72), P30CA015083 (49), U10CA180820 (43), P30CA015704 (33), 2017 (25), 2019 (25), 2018 (22), P30CA033572 (22), 2014 (21), 2025 (21), U10CA032102 (21), U24CA196172 (21), P30CA006973 (20), P30CA022453 (19), P30CA043703 (19)